FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Diabetes Cardiovascular Risk Guidance Committee Meeting

FDA says a two-day meeting of the Endocrinologic and Metabolic Drugs Advisory Committee will consider changes that may be appropriate to a 2008 guidan...

Human Drugs

Companies Weigh-in on Bendeka Exclusivity

Several drug companies respond to FDAs request for comments on how to proceed with Bendeka orphan drug exclusivity in light of a court ruling.

Federal Register

Regulatory Review Period Determined for Siliq

Federal Register notice: FDA determines for patent extension-related purposes the regulatory review period for Kirin-Amgens Siliq (brodalumab).

Federal Register

Regulatory Review Period Determined for Tymlos

Federal Register notice: FDA determines for patent extension-related purposes the regulatory review period for Radius Healths Tymlos (abaloparatide).

Human Drugs

Company Ordered to Stop Selling OTC Drug Products

A federal judge enters a consent decree banning Tennessees Keystone Laboratories from marketing its OTC products until its facility complies with the ...

Human Drugs

FDA Targets Global Web Sites for Illegal Drugs

FDA says that during the recent International Internet Week of Action it targeted 465 Web sites that illegally sold potentially dangerous, unapproved ...

FDA General

Latest FDA Warning Letter

FDA releases its latest batch of Warning Letters that includes one medical product company Auro Pharmacies.

Medical Devices

Safety Alert on Raindrop Near Vision Inlay

A new safety alert warns against an increased risk of corneal haze associated with Optics Medicals Raindrop Near Vision Inlay.

Human Drugs

Review Extended for sBLA for Opdivo/Yervoy

FDA extends by three months its review of a Bristol-Myers Squibb supplemental BLA for an indication in metastatic first-line non-small cell lung cance...

Federal Register

Allergenic Products Advisory Panel Meeting Canceled

Federal Register notice: FDA cancels an 11/7 Allergenic Products Advisory Committee meeting that was scheduled to discuss the use of challenge studies...